MARKET

RLMD

RLMD

Relmada Therapeutics Inc
NASDAQ
3.480
-0.120
-3.33%
Pre Market: 3.670 +0.19 +5.46% 07:35 10/06 EDT
OPEN
3.600
PREV CLOSE
3.600
HIGH
3.700
LOW
3.415
VOLUME
76
TURNOVER
0
52 WEEK HIGH
8.00
52 WEEK LOW
1.803
MARKET CAP
371.21M
P/E (TTM)
-3.6096
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RLMD last week (0928-1002)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 6d ago
Weekly Report: what happened at RLMD last week (0921-0925)?
Weekly Report · 09/28 10:03
Weekly Report: what happened at RLMD last week (0914-0918)?
Weekly Report · 09/21 10:03
Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement
Seeking Alpha · 09/14 18:50
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
NASDAQ · 09/14 13:30
Weekly Report: what happened at RLMD last week (0907-0911)?
Weekly Report · 09/14 10:08
Top Brass Double Down on Relmada Therapeutics in Bold Insider Bet
TipRanks · 09/12 02:04
More
About RLMD
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.

Webull offers Relmada Therapeutics Inc stock information, including NASDAQ: RLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLMD stock methods without spending real money on the virtual paper trading platform.